Adults 21 to 90, any sex, with Rehabilitation or Recovery of Function. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Fugl-Meyer Upper Extremity Assessment (FMA-UE)Primary· Change from baseline at post 6 weeks of intervention
33 item measure of upper extremity (UE) motor control impairment. Total scores were analyzed from 0/66 (indicating a severe impairment, no motor control) to 66/66 (indicating a mild impairment, with near normal motor control)
Group
Value
95% CI
Duck Duck Punch
0.13
± 0.03
Commercially Available Game
0.12
± 0.04
Wolf Motor Function Test (WMFT)Secondary· Change from baseline at post 6 weeks of intervention
The Wolf Motor Function Test contains 15 items, each of which measure upper extremity functional ability by recording the time (seconds) required to accomplish the task. High functional ability is evident in quicker performance times near 0 seconds. Low functional ability is evident in slower performance times near 120 seconds. The assessment is scored by recording the time to perform each of the 15 items (0 seconds to 120 seconds per item), then the average item performance time is calculated. A small average item performance time (near 0 seconds) indicates higher functional ability and thus
Group
Value
95% CI
Duck Duck Punch
0.12
± 0.10
Commercially Available Game
-0.5
± 0.14
Kinematic Variable; Shoulder Flexion-elbow Extension Interjoint CoordinationSecondary· Change from baseline at post 6 weeks of intervention
Shoulder flexion-elbow extension interjoint coordination. Correlation between the shoulder flexion and elbow extension joint angles during a forward reach movement. Values range from -1 (indicating an abnormal flexor synergy pattern, i.e. higher impairment) to 1 (indicating movement similar to a healthy individual, i.e. lower impairment).
Group
Value
95% CI
Duck Duck Punch
-0.02
± 0.20
Commercially Available Game
-0.01
± 0.18
Kinematic Variable; Trunk DisplacementSecondary· Change from baseline at post 6 weeks of intervention
Displacement of the upper trunk marker during reaching task
Group
Value
95% CI
Duck Duck Punch
13.89
± 38.84
Commercially Available Game
-6.02
± 23.73
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data were collected throughout the duration of the study a total of 1 year, and 11 months..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study has 2 parts: In one part of this study, people with stroke will either play a custom designed computer game for stroke rehabilitation called Duck Duck Punch or an off the shelf computer game with their weaker arm 3 times per week for 6 weeks. Evaluations will determine whether or not one computer game improved arm movement more than the other. In the second part of the study, people with stroke, caregivers of people with stroke and stroke rehabilitation therapists will meet in several focus groups to design a useful and informative Duck Duck Punch performance report.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07450274 — Rehabilitation of Upper Limbs After Stroke
· NA
· recruiting
NCT07419217 — Professional Impact of Osteoarticular Trauma
· recruiting
NCT07399262 — Music-Augmented Rhythmic Gait Training in Multiple Sclerosis
· NA
· recruiting
NCT07333079 — Rehabilitation With Biofeedback for People After Stroke
· NA
· recruiting
NCT07304180 — Exergame vs Balance Training in Hemiplegia
· NA
· active not recruiting
Other Medical University of South Carolina trials
Trials by the same sponsor.
NCT06491264 — Multiparameter Optimized tES for Memory in Aging
· NA
· withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
· Phase 2
· not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE)
· NA
· not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
· Phase 2
· recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 3 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03053492.